All Type of News
Government seeking health insurance reform
Korea’s health insurance will not be sustainable if nothing is done to improve its finances. Losses are destined to snowball. As the losses are covered by government subsidies, they will put an enormous strain on the ...
Diabetes drug market in transition
Handok Pharmaceutical’s Amaryl kept its number 1 ranking in local diabetes drug market, but struggles this year against Merck’s Januvia (sitagliptin) which succeeded in overtaking the top position in October.
Januv...
Korea Drug Logistics Cooperative to select preferred bidder
An organizer of the Korea Drug Logistics Cooperative said Thursday that it will pick a preferred bidder among three potential buyers to buy a controlling stake in the cooperative, as part of its efforts to promote the...
Revision of Pharmaceutical Affairs Law hits snag
A bill to revise the Pharmaceutical Affairs Law, designed to allow the sale of painkillers and cold medicines at convenience stores, is unlikely to be endorsed within this year as lawmakers from the Grand National Par...
Drug makers to hold rally against massive drug cuts
Korean pharmaceutical companies and related interest groups will stage a mass-scale rally on November 18 to step up their protests against the government’s measure designed to reduce insurance expenditures starting ne...
Listed pharmaceutical firms recruited 1,000 this year
A total of 54 pharmaceutical firms listed on the local KOSPI and KOSDAQ markets hired about 994 new employees between September 2010 and September 2011.
A report released by Yakup.com showed that the number of new ...
Multinational firms seeking to place priority on new drug pricing system
Despite the local pharmaceutical industry’s scheme to hold a large-scale rally tomorrow to protest against the government’s massive drug prices cut plan, multinational firms here decided not to join the rally.
Mult...
Drug makers spend 35.3% of revenue on promotion in 3 quarter
Details of drug company spending in the third quarter of this year revealed recently show that the country's 47 listed pharmaceutical companies on average spend 35.3 percent of their annual revenue on marketing and ho...
KOSPI-listed pharmaceutical firms’ operating profit plunge by 8.9% in third quarter
Korea’s listed pharmaceutical companies saw their third-quarter combined operating profit fall 6.8 percent year-on-year, while net profit dwindle to 14.3%. Sales were up 6.1 percent on average.
The combined net pro...
Januvia, Galvus, Onglyza and Trajenta vie for market share in Korea
Multinational pharmaceutical companies will step up their marketing in the domestic dipeptidyl peptidase-IV (DPP-IV) inhibitors market dominated by Merck’s Januvia (sitagliptin) and Novartis’s Galvus (vildagliptin), w...
